How much does Ado-trastuzumab emtansine cost?

Ado-trastuzumab emtansine, also known as T-DMI, was the first antibody-directed chemotherapy drug approved for solid malignancies. It was approved by the U.S. Food and Drug Administration (FDA) in 2013. The relatively rapid development of this new drug reflects the demand and excitement for targeted therapies that do not harm normal tissue but provide better efficacy than traditional cytotoxic drugs. Trastuzumab can be used in people diagnosed with HER2-positive metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy, or after surgery in people diagnosed with early-stage HER2-positive breast cancer who have received trastuzumab and taxane chemotherapy before surgery and have residual disease discovered during surgery. Metastatic breast cancer is breast cancer that has spread to other parts of the body away from the breast, such as the bones or liver.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. The Turkish version is launched overseasEnmetratrastuzSpecifications of single antigenic drugThe price of 100mg per box may be more than 3,000 yuan, and the price of the European version of 100mg per box may be more than 8,000 yuan. The price of each box of 160 mg may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold at home and abroad are basically the same. Currently, there are no generic drugs of Enmei Trastuzumab produced and launched.